CSPC Pharmaceuticals Group ADR (CSPCY) Stock Price & News

CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia

About CSPC Pharmaceuticals Group ADR

CEOZhang Cuilong

Employees18.6K

Founded1992

Headquarters-

SectorPharmaceutical industry

Websitecspc.com.hk

All values in CNY	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	6.62B	6.11B	6.47B	12.13B
Cost of goods sold	2.28B	2.11B	2.20B	2.24B
Cost of revenue	2.28B	2.11B	2.20B	2.24B
Research and development expenses	1.50B	1.62B	1.40B	1.63B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.97B	1.87B	1.89B	1.89B
Operating expense	3.47B	3.49B	3.29B	3.51B
Total operating expenses	5.75B	5.60B	5.49B	5.75B
Operating income	869.63M	514.71M	973.82M	6.38B
Other non operating income	645.49M	-470.42M	181.80M	11.92M
EBT including unusual items	1.18B	505.59M	1.13B	6.40B
EBT excluding unusual items	1.37B	186.56M	1.13B	6.35B
Income tax expense	222.47M	165.64M	243.25M	825.70M
Effective tax rate	18.78%	32.76%	21.46%	12.91%
Other operating expenses	-	-	-	-
Net income	963.54M	370.72M	859.79M	5.23B
Net profit margin	14.56%	6.06%	13.30%	43.16%
Earnings per share	-	-	-	-
Interest and investment income	-	195.87M	-	91.68M
Interest expense	-105.19M	-6.76M	-11.01M	-2.30M
Net interest expenses	-105.19M	189.12M	-11.01M	89.37M
Depreciation and amortization charges	-	-	-	-
EBITDA	1.14B	802.06M	1.26B	6.67B
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything